Quarterly ResultAug 3, 2026, 07:12 AM
Ocular Therapeutix Q2 Net Loss $(78.8)M; AXPAXLI NDA on Track
AI Summary
Ocular Therapeutix reported a net loss of $(78.8) million, or $(0.35) per share, on total net revenue of $13.5 million for Q2 2026, which was flat year-over-year. Despite increased operating expenses, the company confirmed its AXPAXLI wet AMD NDA submission is on track for Q4 2026, supported by positive FDA Type C meeting minutes and a new post-hoc SOL-1 analysis demonstrating significant treatment burden reduction. The company also announced amendments to its SOL-R trial, pushing topline results to Q1 2028, and streamlined its diabetic retinopathy program.
Key Highlights
- AXPAXLI wet AMD NDA submission remains on track for Q4 2026, following positive FDA Type C meeting.
- New post-hoc SOL-1 analysis shows up to 72% reduction in treatment burden with AXPAXLI over 60 weeks.
- Cash balance was $598.6 million as of June 30, 2026, with expected runway into 2028.
- Total net revenue for Q2 2026 was $13.5 million, flat compared to Q2 2025.
- Net loss for Q2 2026 was $(78.8) million, or $(0.35) per share.
- R&D expenses increased to $54.1 million in Q2 2026 from $51.1 million in Q2 2025.
- SOL-R (Phase 3, wet AMD) topline results now expected in Q1 2028 due to trial amendments.
- HELIOS-3 (Phase 3, NPDR) trial size reduced to 620 patients, evaluating AXPAXLI dosed every 12 months.
Price Impact
More from OCUL